Ah the Saturday morning Stoney. Always a good read. Comments: -I do like that $12 stock. GBDC. We'll dig into that one. OSUR too. -"Evercore analyst Vijay Kumar and colleagues". Another movie reference. Think White Castle and Gitmo. -I really don't like that Israeli company Stoney, Kamada. No good reason, its just this whole Covid thing is ripe for scams. Plus it sounds too much like Kamala so your theory about Trump helping them out... he'll misread it and tweet something stupid and down they'll go. Do you have Goodyear tires on your Jeep btw? Regarding colorful CEO conference calls lol... you should listen to a few of $FIZZ's . National Beverage Corp. They make LaQroix plus a ton of other brands of fruit and energy drinks. That CEO is a nut. He gets the prize for the goofiest things ever said on a quarterly. Its interesting though, I have not looked at the stock in awhile, but I used to really follow it. The last time I discussed it here on ET, last year, that CEO (he's the founder too) was buying the stock hand over foot in the low $40's. I just looked, its $69 now. (don't miss that last line below) FIZZ earnings: What are they drinking at National Beverage? Jane Wells | @janewells Published 4:31 PM ET Fri, 6 Sept 2013 Updated 4:58 PM ET Fri, 6 Sept 2013 CNBC.com When companies have a bad quarter, they often sugarcoat results with fancy language and fuzzy math. Special one-time items are a great excuse to make a loss look like a profit. However, at National Beverage, they call a spade a spade. I think. I'm still trying to understand. … In what may be the strangest earnings release ever, the company behind such colas as Shasta reported a 6 percent drop in revenue and a 16 percent drop in earnings for its fiscal first quarter. "National Beverage Reports Less Than Typical Results" was the headline of the Florida company's press release. (Read more from Jane Wells: LavCup—Why didn't I think of this?) Then the Chairman and CEO Nick Caporella weighed in. Fasten your seatbelts: "Should we have the most credible reason for these results (and we could have), would it make a difference?" asked Nick A. Caporella, Chairman and Chief Executive Officer on a recent management call. "Does it make us feel less contrite relative to the credibility of the justification?" he queried. "There can be no allowable regrets in business or fumbles on the field (deck) of Endeavor—none ... (no one even knows how to practice them)," quipped Caporella. I had to read that a couple times and I'm still not sure what that means, but I think he's upset and not making excuses. Kinda. I called the company's headquarters and spoke to Grace Keene, who confirmed Caporella made these statements. Here's more of what he said in the release: "From mega retailers to soft drink giants, the summer of '13 will symbolically claim its victims! Consequently, the culmination of nervousness of a 'whiplashed' consumer to the 'knee jerk' reaction of Big Cola ... all segments of soft drink sales were affected—as retailers and soft drink companies subsequently disclosed. The lowering of prices being Big Cola's response—further complicated the situation! Cooler weather compounded already weakened consumer spirits," indicated Caporella. When I asked Keene for more context—when were these statements made, what was the motivation, is this not unusual—she said she had no additional comment. This isn't the first time Caporella has made interesting remarks. In reporting full-year earnings in July, he said, "This was a year that witnessed consumer trends/mood severely change their preferences. It is very tempting to write about all the challenges; from corn costs to horrific explosions—to fear-induced bomb or tornado catastrophes, but why do that? Instead, we count our blessings for results that are far better than our industry peers anticipated." Apparently, though, the fizz has gone out of the soda business since. Even though "Good soft drinks are to the human race what sunshine is to a picnic!" the CEO admitted that consumers have less disposable income. "Maybe everyone learned an invaluable lesson—'No instant fix for a distraught consumer!' However, ever the optimist, Caporella sees trends improving. The press release ends with his insistence that "no mental degradation has occurred!", and we are left with these thoughts from a guy who may be the most unusual CEO since Andrew Mason did yoga in his underwear while running Groupon: "Certainly, we have come to know—precious rainbows usually require both rain and sunshine! Team National's results were obtained by diligence and untiring determination. We are Disappointed—Yes; Contrite—Certainly; Resilient—Absolutely. ..." Come to think of it, wouldn't it be nice if more CEOs were this honest? —By CNBC's Jane Wells; Follow her on Twitter: @janewells
I'll tell you another stock that the CEO and founder keeps buying tons of. He bought a bunch in the $20's and he's bought a bunch down here in the $14's. Its in the energy infra-structure sector. Kinder-Morgan. $KMI Of course he's the richest man in Houston so what's 20 or 30 million to him anyway, but still. 7.3% dividend, ya gotta like that. He won't cut it either. They own lots of natural gas pipelines and storage facilities. That's the future on the way to a greener climate. Or at least a stepping stone. Let's keep an eye on KMI Stoney.
YOU DON'T LIKE KAMADA!!!! --BREAKING NEWS STONEY WAS RIGHT FDA DOES 180 TURN IN 2 DAYS!!! -- I EVEN TRUMPED UP THE TRUMP STUFF--- AM I ESP? Am I Fever Mind, The Fury.... "On the therapeutics front...in our battle against the China virus that will save countless lives, the FDA has issued an emergency use authorization — and that's such powerful term, emergency use authorization — for a treatment known as convalescent plasma," President Trump said at a press briefing today. Plasma another great word it's in TV's you know. Ever watched a game on a plasma TV... it's powerful. Supremely powerful. The therapy "transfuses very, very strong antibodies from the blood of recovered patients to help treat patients battling a current infection," he explained. And it's yellow and kind of yucky looking. The authorization will "dramatically expand access to this treatment," he added. And I would think greatly aid a certain Israel based biotech... FDA has determined that the treatment is safe "and very effective," Trump said. Effective is such a powerful word. "We saw about a 35% better survival in the patients who benefited most from the treatment, which were patients under 80 who were not on artificial respiration," Health and Human Services Secretary Alex Azar said at the briefing. "This is a major advance in treatment of patients," he added. Azar said the FDA expects other new options and treatments available to patients as early as this fall. .... Ok Now is the time CEO of Kamada if you have numbers on the trial TOMORROW WOULD BE THE PERFECT DAY!!! IF I can get a Press Release tomorrow from KMDA and good news from the trial tied into this FDA turn around and Trump involvement... I might just have done it.. we'll see....
Good morning stonedinvestors I threw up this morning. Throwing up before trading is a time honored tradition and it indicates heightened stress and poor eating habits. Check & Check. GrowGeneration falls after CEO Lampert sells $3.87M of shares 08:01 GRWG GrowGeneration CEO Darren Lampert disclosed the sale of 218,000 shares for prices of $19.39 and $16.53 on August 20 and 21, respectively. Lampert continues to own 1,113,914 shares of GrowGeneration. The stock in premarket trading is down 12% to $15.20. GrowGeneration was the subject of a short report Friday from Hindenburg Research and subsequently announced it will take legal action against the firm. Kamada, ADMA Biologics soar on FDA COVID authorization for convalescent plasma 07:12 KMDA, ADMA Shares of Kamada (KMDA) are up 22.6% at $12.26 and ADMA Biologics (ADMA) are up 72.6% at $4.36 in early pre-market trade following yesterday's FDA announcement issuing COVID-19 emergency use authorization for convalescent plasma. The companies are among the potential beneficiaries given their efforts in plasma-derived therapeutics and plasma collection in COVID-19.
Juicy Upgrade- On a stock we talked about Van.... remember used cars? ALLY)))))) Stephens would be long Ally Financial into CFO presentation at conference 06:48 ALLY, SC Stephens analyst Vincent Caintic said he would be long on Ally Financial (ALLY) shares ahead of the next catalyst he sees for the stock, namely an upcoming presentation by the company's CFO at an investors conference on September 15. Caintic, who noted that he sees recent positive trends on used car prices as well as Santander Consumer's (SC) 75% recovery rate as positive for Ally's Q3 earnings, keeps an Overweight rating and $28 price target on Ally >>
Kamada is all about their plasma it would seem. Hmmm. I think you did it again Stoney. The damn thing is up 24% 3 minutes to the bell.
Day Watch Top Gainers 1D chg ADMAADMA Biologics, Inc.37.90% LMNLLiminal BioSciences, Inc.32.68% KMDAKamada Ltd.30.90%<---------------#3!!!!!!!! I accepted a challenge to replicate the Grow Generation Trade by AGAIN nailing the top gainer on the Nsdaq. With the extreme number of stocks out there this is almost an impossible task. I have come close.
Time to check in on our perennial dog GWPH Stoney. It's down to $109. Any thoughts? Didn't one of our boys put a $500 target on that thing? Lemmee look here. EDIT: Ok $275